分析免疫治疗联合放射性125I粒子植入治疗晚期肺癌患者的临床安全性

Analysis of the Clinical Safety of Immunotherapy Combined with Radioac⁃tive 125I Particle Implantation in the Treatment of Advanced Lung Cancer Patients

目的 分析晚期肺癌实施免疫治疗+放射性125I粒子植入的影响。方法 目的选取2023年1月-2024年1月即墨区人民医院66例晚期肺癌患者为研究对象,按治疗方法分为单一组、综合组,每组33例,单一组行放射性~(125)I粒子植入,综合组则加用免疫治疗。观察近远期疗效,测定肿瘤直径并统计不良事件。结果 综合缓解率组为57.58%(19/33),控制率为78.79%(26/33),均高于单一组的30.30%(10/33)和54.55%(18/33),差异有统计学意义(χ^(2)=4.982、4.364,P均<0.05)。治疗后综合组无进展生存期远长于单一组,综合组肿瘤直径短于单一组,差异有统计学意义(P均<0.05)。综合组肝肾损害率、皮疹率、白细胞减少率、其他不良事件率和单一组比较,差异无统计学意义(P均>0.05)。结论 以放射性125I粒子植入为基础加用卡瑞利珠单抗治疗的缓解率高,且能控制晚期肺癌的发展,双重治疗的安全性高,还可缩小病灶直径。

Objective To analyze the effects of immunotherapy combined with radioactive 125I particle implantation on advanced lung cancer.Methods A total of sixty-six patients with advanced lung cancer in the People′s Hospital of Jimo District from January 2023 to January 2024 were objectively selected as the study subjects.They were divided into a single group and a comprehensive group by different treatment method,with thirty-three cases each.The single group received radioactive 125I particle implantation,while the comprehensive group received immunotherapy.The short-term and long-term therapeutic effects were observed.The tumor diameter was measured and adverse events were recorded.Results After statistical analysis,the remission rate was 57.58%(19/33)in the comprehensive group,and the control rate was 78.79%(26/33)in the comprehensive group,both higher than the single group 30.30%(10/33)and 54.55%(18/33),the differences were statistically significant(χ^(2)=4.982,4.364,both P<0.05).The progression free survival in the comprehensive group was much longer than the single group,the tumor diameter in the comprehen-sive group was shorter than that in the single group,the differences were statistically significant(both P<0.05).There was no statistically significant difference in the liver and kidney damage rate,rash rate,leukopenia rate,other adverse events rate between two groups(all P>0.05).Conclusion Based on the implantation of radioactive 125I particles and the addition of Carolizumab,the response rate is high,and it can control the development of advanced lung cancer.The safety of dual treatment is high,and it can reduce the lesion diameter.